Antipsychotic polytherapy on an inpatient psychiatric unit: How does clinical practice coincide with Joint Commission guidelines?

General Hospital Psychiatry

Volumn 33, Issue 5, 2011, Pages 501-508

  Huffman, Jeff C ^a,b   Chang, Trina E ^a,b   Durham, Lauren E ^b   Weiss, Anthony P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antipsychotics; Inpatient; Polypharmacy; Psychosis; Quality

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEALTH CARE QUALITY; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SERVICE; MENTAL DISEASE; MENTAL HEALTH CARE; PATIENT IDENTIFICATION; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIC DEPARTMENT; PSYCHOSIS;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS; LENGTH OF STAY; MALE; MEDICAL AUDIT; MENTAL DISORDERS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; TREATMENT FAILURE; UNITED STATES;

EID: 80052713621     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2011.05.012     Document Type: Article

References (23)

1. The Joint Commission Joint Commission national quality core measures - hospital based inpatient psychiatric services (HBIPS) core measure set 2008, Available at. http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/Hospital+Based+Inpatient+Psychiatric+Services.htm.
2. Gilmer T.P., Dolder C.R., Folsom D.P., Mastin W., Jeste D.V. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007, 58:1007-1010.
3. Brooks J.O., Goldberg J.F., Ketter T.A., et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the systematic treatment enhancement program for bipolar disorder. J Clin Psychiatry 2011, 72:240-247.
4. Kogut S.J., Yam F., Dufresne R. Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. J Manag Care PHarm 2005, 11:17-24.
5. Centorrino F., Goren J.L., Hennen J., et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004, 161:700-706.
6. Correll C.U., Rummel-Kluge C., Corves C., Kane J.M., Leucht S. Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009, 35:445-457.
7. Biancosino B., Barbui Bm Marmai L., Dona S., Grassi L. Determinants of antipsychotic polypharmacy in psychiatric inpatients. Int Clin Psychopharmacol 2005, 20:305-309.
8. Centorrino F., Cincotta S.L., Talamo A., et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry 2008, 49:65-69.
9. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004, 65:1377-1388.
10. Centorrino F., Fogarty K.V., Sani G., Salvatore P., Cincotta S.L., Hennen J., et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol 2005, 20:485-492.
11. Weiner E., Conley R.R., Ball M.P., et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010, 35:2274-2283.
12. Benedetti A., Di Paolo A., Lastella M., et al. Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study. Clin Pract Epidemiol Ment Health 2010, 6:30-35.
13. Lehman A.F., Lieberman J.A., Dixon L.B., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161:1-56.
14. Shelton R.C., Papakostas G.I. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 2008, 117:253-259.
15. Pae C.U., Lim H.K., Peindl K., et al. The atypical antipsychotic olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 2008, 23:1-8.
16. Skapinakis P., Papatheodorou T., Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007, 17:79-93.
17. Thase M.E., Macfadden W., Weisler R.H., et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the Bolder II study). J Clin Psychopharmacol 2006, 26:600-609.
18. Depping A.M., Komossa K., Kissling W., Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010, (12):CD008120.
19. Wine J.N., Sanda C., Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother 2009, 43(4):707-713.
20. Kuehn B.M. FDA panel issues mixed decision on quetiapine in depression and anxiety. JAMA 2009, 301:2081-2082.
21. Cates M.E., Jackson C.W., Feldman J.M., Stimmel A.E., Woolley T.W. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J 2009, 45:251-254.
22. Stowell K.R., Ghinassi F.A., Fabian T.J., Nash K.C., Haskett R.F. Best practices: an intervention to promote evidence-based prescribing at a large psychiatric hospital. Psychiatr Serv 2009, 60:294-296.
23. McCarney R., Warner J., Iliffe S., van Haselen R., Griffin M., Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol 2007, 7:30.